Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Rating) have been given a consensus recommendation of “Buy” by the six research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $6.06.
A number of brokerages have issued reports on CDTX. HC Wainwright cut their target price on shares of Cidara Therapeutics from $7.50 to $6.00 in a research report on Thursday, May 12th. StockNews.com began coverage on shares of Cidara Therapeutics in a research report on Wednesday. They set a “hold” rating for the company.
Institutional Investors Weigh In On Cidara Therapeutics
A number of institutional investors have recently bought and sold shares of CDTX. Jeppson Wealth Management LLC lifted its position in Cidara Therapeutics by 25.9% during the second quarter. Jeppson Wealth Management LLC now owns 181,075 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 37,225 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Cidara Therapeutics by 64.9% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 88,097 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 34,666 shares in the last quarter. US Bancorp DE acquired a new position in shares of Cidara Therapeutics during the second quarter worth $128,000. State Street Corp lifted its position in shares of Cidara Therapeutics by 14.1% during the first quarter. State Street Corp now owns 176,237 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 21,837 shares in the last quarter. Finally, Laurion Capital Management LP acquired a new position in shares of Cidara Therapeutics during the fourth quarter worth $252,000. 58.20% of the stock is currently owned by hedge funds and other institutional investors.
Cidara Therapeutics Price Performance
Cidara Therapeutics (NASDAQ:CDTX – Get Rating) last announced its quarterly earnings data on Wednesday, August 10th. The biotechnology company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.09. Cidara Therapeutics had a negative net margin of 239.94% and a negative return on equity of 1,522.85%. As a group, sell-side analysts forecast that Cidara Therapeutics will post -0.69 earnings per share for the current year.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
- Get a free copy of the StockNews.com research report on Cidara Therapeutics (CDTX)
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- Exxon, Occidental Petroleum Lead Heavy Month Of Insider Buying
- Why Apple is Primed to Take a Bite Out of Live Sports
- Home Depot Results Point To Sluggish 2nd Half
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.